Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Saputo Inc. Stock Outperforms Market Despite Losses On The Day

Saputo Inc. Stock Outperforms Market Despite Losses On The Day

Dow JonesDow Jones2026/11/03 21:35

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Saputo Inc. SAP slid 0.32% to C$41.10 Tuesday, in what proved to be an all-around down trading session for the Canadian market, with the S&P/TSX Composite Index falling 0.75% to 35,532.28.

Saputo Inc. closed 8.8% below its 52-week high of C$45.09, which the company achieved on April 10th.

Trading volume of 451,959 shares remained below its 50-day average volume of 660,801.

Data source: Dow Jones Market Data, FactSet. Data compiled November 3, 2026.

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

November 03, 2026 16:35 ET (21:35 GMT)

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Dental treatment company vVardis has announced the terms for its $214 million US IPO.

智通财经•2026/11/09 06:41
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss

Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.

智通财经•2026/11/09 06:41
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss